PharmaOnco™ CHO-Tg(Human PD-L1//TCR Activator) Stable Cell Line, Single Clone (CAT#: ITS-0822-HMM196)

Creative Biolabs offers CHO-Tg(Human PD-L1//TCR Activator) stable cell line which the PD-L1 and TCR Activator gene stably expressed in CHO cells.

The CHO-Tg(Human PD-L1/TCR Activator) stable cell line is a genetically modified Chinese hamster ovary (CHO) cell line that has been engineered to constitutively express both human PD-L1 (Programmed Death-Ligand 1) and a T cell receptor (TCR) activator. PD-L1 is a immune checkpoint protein that inhibits T cell activation, while the TCR activator is designed to stimulate T cell response. This stable cell line can be used in research and drug development to study the interaction between PD-L1 and TCR signaling pathways, as well as to screen potential immunotherapies targeting these pathways.

Consistent gene expression;
Reliability and reproducibility;

Functional assay

PD-L1//TCR Activator

Human

CHO

GenBank accession #NM_014143

The PD-1 gene, also known as programmed cell death protein 1, is a gene that encodes a protein found on the surface of T cells and other immune cells. PD-1 plays a crucial role in regulating the immune response by inhibiting T cell activity and preventing autoimmunity. However, overexpression of PD-1 can also suppress the immune response against cancer cells, allowing tumors to evade detection and destruction by the immune system. Therapies targeting PD-1, such as checkpoint inhibitors, have been developed to block the interaction between PD-1 and its ligands, releasing the brakes on the immune response and helping the body's immune system to attack and eliminate cancer cells. These treatments have shown significant success in treating various types of cancer, including melanoma, lung cancer, and lymphoma.
TCR (T cell receptor) activators are compounds or molecules that stimulate the activation of T cells in the immune system. T cells play a crucial role in the immune response by recognizing and attacking infected cells or foreign invaders. TCR activators can enhance the ability of T cells to detect and eliminate harmful pathogens or cancer cells.